AnaptysBio, Inc. (ANAB)
| Market Cap | 1.91B |
| Revenue (ttm) | 234.60M |
| Net Income (ttm) | -13.23M |
| Shares Out | 28.75M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | 55.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,378 |
| Open | 67.16 |
| Previous Close | 66.59 |
| Day's Range | 65.54 - 71.67 |
| 52-Week Range | 17.11 - 73.30 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 71.67 (+7.95%) |
| Earnings Date | May 8, 2026 |
About ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid ... [Read more]
Financial Performance
In 2025, AnaptysBio's revenue was $234.60 million, an increase of 157.01% compared to the previous year's $91.28 million. Losses were -$13.23 million, -90.89% less than in 2024.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price target is $71.67, which is an increase of 7.95% from the latest price.
News
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announ...
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its f...
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics...
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase ...
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the...
AnaptysBio Transcript: Leerink Global Healthcare Conference 2026
A corporate split will create a royalty-focused parent and a biopharma spin-off, with the latter advancing ANB033 in celiac disease and EoE. Jemperli royalties are set to grow rapidly, and key clinical data for ANB033 is expected in Q4. Litigation with GSK could impact future royalty streams.
AnaptysBio Transcript: Barclays 28th Annual Global Healthcare Conference
A major restructuring will create a new biopharma company focused on advancing antibody programs, while the legacy entity becomes a high-margin royalty business. Key assets include ANB033 for celiac disease and EoE, with pivotal data expected in late 2024 and 2027, and a robust royalty stream from Jemperli.
AnaptysBio Transcript: TD Cowen 46th Annual Health Care Conference
The company is finalizing a split into a royalty business and a biopharma operation, with JEMPERLI royalties and a robust pipeline including ANB033 and ROSNILIMAB. Key clinical data readouts and a major litigation outcome are expected in 2024, positioning both entities for growth.
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac diseas...
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics Li...
AnaptysBio Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium
The business is on track to separate its royalty and biopharma operations in Q2, with the royalty arm anchored by strong Jemperli growth and the biopharma arm advancing a robust pipeline. Key clinical readouts and strategic decisions on cash allocation and partnerships are expected in 2024.
AnaptysBio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
A planned Q2 split will create two focused entities: a biopharma business advancing three clinical programs and a royalty business anchored by Jemperli and imsidolimab. Key clinical data for celiac disease is expected in Q4, while the royalty business benefits from strong Jemperli growth.
Anaptys Announces Participation at Upcoming Investor Conferences
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...
AnaptysBio Transcript: 44th Annual J.P. Morgan Healthcare Conference
A planned Q2 separation will create two focused entities: one managing royalty streams from JEMPERLI and imsidolimab, and another advancing a pipeline led by ANB033 and rosnilimab. Key clinical data and strategic partnerships are anticipated in 2024, with strong financial positioning and a clear rationale for unlocking shareholder value.
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sa...
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to...
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administr...
AnaptysBio Transcript: Evercore ISI 8th Annual HealthCONx Conference
Plans are underway to split the royalty and biopharma businesses in 2026, with each designed for independent resilience. ANB033 and Rosnilimab are advancing in clinical development, while the royalty business expects strong cash flow and ongoing litigation with GSK is not expected to impact operations.
AnaptysBio Transcript: Piper Sandler 37th Annual Healthcare Conference
Plans are underway to split into royalty and biopharma businesses by 2026, with operational and financial preparations progressing. Key programs include ANB033 for celiac disease, with phase I-B data expected next year, and rosnilimab for RA, advancing toward phase III.
Anaptys Announces Participation in December Investor Conferences
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a par...
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.
GSK, AnaptysBio Sue Each Other Over Cancer Drug License
The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.
Anaptys Announces $100 Million Stock Repurchase Plan
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...